| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802944001055 | 294400105 | GALANTAMINE/PHARMATHEN PR.CAP 8MG/CAP BTx30 | 6.19 | 6.49 | 8.95 |
| 05/2018 | 2802944002052 | 294400205 | GALANTAMINE/PHARMATHEN PR.CAP 16MG/CAP BTx30 | 8.20 | 8.60 | 11.85 |
| 05/2018 | 2802944003059 | 294400305 | GALANTAMINE/PHARMATHEN PR.CAP 24MG/CAP BTx30 | 8.59 | 09.01 | 12.41 |
For the treatment of mild to moderate dementia of the Alzheimer's type. Has also been investigated in patients with mild cognitive impairment who did not meet the diagnostic criteria for Alzheimer's disease.
Galantamine is a phenanthrene alkaloid and a reversible, competitive acetylcholinesterase inhibitor. It is not structurally related to other acetylcholinesterase inhibitors. Galantamine's proposed mechanism of action involves the reversible inhibition of acetylcholinesterase, which prevents the hydrolysis of acetycholine, leading to an increased concentration of acetylcholine at cholinergic synapses. Galantamine also binds allosterically with nicotinic acetylcholine receptors and may possibly potentiate the action of agonists (such as acetylcholine) at these receptors.
LD<sub>50</sub>=75 mg/kg (rat)
7 hours
Galantamine is metabolized by hepatic cytochrome P450 enzymes, glucuronidated, and excreted unchanged in the urine.
* 175 L
* 300 mL/min [After IV. or oral administration]